CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioAxone BioSciences, Inc. , an emerging, clinical-stage biotechnology company focused on developing innovative drugs to treat spinal cord injury and restore neurological function, today announced that CEO Lisa McKerracher has accepted an offer to join the Consortium Advisory Panel (CAP) for the Christopher & Dana Reeve Foundation. In her new role, Dr. McKerracher will direct the foundation’s focus toward the identification, development and translation of potential Spinal Cord Injury (SCI) therapies into the clinic. The Christopher Reeve Foundation wrote about Dr. McKerracher’s accomplishments in a recent blog post.
“This is a great honor,” said Lisa McKerracher, Ph.D., CEO of BioAxone BioSciences. “The SCI community is really special to me and joining this Advisory Board with the Reeve Foundation helps our shared goal of advancing therapies for patients with SCI.”
Susan P. Howley, Executive Vice President Research, of the Christopher & Dana Reeve Foundation commented, “We are thrilled that Lisa has joined the Advisory Board of the Reeve Foundation. Her advancements and dedication to the SCI field is something we greatly admire. We look forward to continued progress toward our goals with her help.”
About the Reeve Foundation:
The Christopher & Dana Reeve Foundation is dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for people living with paralysis through grants, information and advocacy. The Paralysis Resource Center (PRC) is the support side of the Reeve Foundation’s twin missions to provide “Today’s Care” and to strive for “Tomorrow’s Cure” and offers a free, comprehensive, national source of informational support for individuals living with paralysis and their caregivers. For more information, visit www.christopherreeve.org
About BioAxone BioSciences
BioAxone BioSciences is an emerging, clinical-stage biotechnology company developing innovative drugs to restore neurological function for patients with Spinal Cord Injuries (SCI) and vascular malformations in the central nervous system and glaucoma. Led by a team of scientists renowned for their work on axon regeneration and neuronal signaling pathways, BioAxone has a pioneering SCI drug currently in a Phase IIb/III clinical trial with our partner, Vertex, and is positioned to move other candidates into clinical trials. BioAxone seeks global partners for a novel pipeline of first in class compounds for neurological diseases with compromised blood-brain barrier function and for glaucoma. For more information, visit www.bioaxonebio.com